Antiinflammatory cell adhesion inhibitors
    1.
    发明授权
    Antiinflammatory cell adhesion inhibitors 失效
    抗炎细胞粘附抑制剂

    公开(公告)号:US6110897A

    公开(公告)日:2000-08-29

    申请号:US948294

    申请日:1997-10-10

    IPC分类号: C07H7/027 A61K31/70 C07H15/00

    CPC分类号: C07H7/027

    摘要: The invention relates to compounds of formula Ix and Ia: ##STR1## wherein (Ix) comprises the regioisomeric form sLe.sup.X and (Ia) comprises the regioisomeric form sLe.sup.A, and R.sup.1 is a lipophilic radical formed from aliphatic or cycloaliphatic units, or a sugar residue which is capped by a .beta.1-O-linked aliphatic or cycloaliphatic unit at the reducing end of the terminal sugar. The compounds of the present invention are useful as inhibitors of increased cell-cell adhesion as well as useful in treating diseases associated with increased cell-cell-adhesion. The compounds of the present invention are also incorporated into pharmaceutical compositions.

    摘要翻译: 本发明涉及式Ix和Ia的化合物:其中(Ix)包含区域异构形式的sLeX,(Ia)包含区域异构形式的sLeA,并且R 1是由脂族或脂环族单元形成的亲脂基团,或被封端的糖残基 通过在末端糖的还原端的β1-O-连接的脂族或脂环族单元。 本发明的化合物可用作增加的细胞 - 细胞粘附的抑制剂,并且可用于治疗与增加的细胞 - 细胞粘附相关的疾病。 本发明的化合物也并入药物组合物中。

    Polymer-conjugated malonic acid derivatives and their use as medicaments
and diagnostic agents
    4.
    发明授权
    Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents 失效
    聚合物共轭丙二酸衍生物及其作为药物和诊断剂的用途

    公开(公告)号:US5817742A

    公开(公告)日:1998-10-06

    申请号:US718524

    申请日:1996-09-11

    摘要: Polymer-based polyvalent malonic acid derivatives having anti-adhesive properties are described. The compounds comprise a polyamino acid linked to a group of formula (I). In formula (I), R.sup.1 and R.sup.2 together form a six-membered carbocylic or heterocyclic ring, containing at least one substituent selected from R.sup.4, R.sup.5, and R.sup.6. R.sup.3 is H, (CH.sub.2) .sub.m X or CH.sub.2 O(CH.sub.2).sup.m X.sup.1. The polyamino acid and the group of formula II are linked via R.sup.4, R.sup.5, or R.sup.6, or optionally via a spacer of formula --�Q.sup.1 --(CH.sub.2).sub.p --Q.sup.2 --!.sub.r. A and B independently are O, S, NH, HN--CO, OC--NH, O--CO, OC--O, NH--CO--O, --O--CO--NH, S--CO, SC--O, O--CS--S, S--CS--OS, NH--CS--S, S--CS--NH, or CH.sub.2. Z is a pyranose, furanose, open-chain polyalcohol or Y--X.sup.6. Y is --O--(CX.sup.2,X.sup.3).sub.n, -(CX.sup.2,X.sup.3).sub.n, --CH.sub.2 --(CX.sup.2,X.sup.3).sub.n or a saturated or unsaturated six-membered carbo- or heterocyclic group having at least one substituent R.sup.9, or a combination of the chain --O--(CX.sup.2,X.sup.3).sub.n, or -(CX.sup.2,X.sup.3).sub.n, and the carbocyclic or heterocyclic group, in which R.sup.4, R.sup.5, and R.sup.6 independently are H, OH, --O--(CH.sub.2) .sub.q X.sup.4, --CH.sub.2 O(CH.sub.2) .sub.q X.sup.5, or HNC(O)CH.sub.3, and X, X.sup.1, X.sup.2, and X.sup.3 independently are H, NH.sub.2, COOH, OH, CH.sub.2 OH, CH.sub.2 NH.sub.2, C.sub.1 -C.sub.20 -alkyl, or C.sub.6 -C.sub.10 -aryl, X.sup.4 and X.sup.5 independently are --NH-- or --O--, and X.sup.6 is OH or --C(R.sup.3) (COOH).sub.2. m, n, and q independently can be 1-20. In the linker, Q.sup.1 is CH.sub.2 or --CO--, Q.sup.2 is --NH-- or --CO--NH--, p is 1-6, and r is 0 or 1. Methods of preparing the compounds, and their use as medicaments or diagnostic agents also are disclosed. ##STR1##

    摘要翻译: PCT No.PCT / EP95 / 00844 Sec。 371日期:1996年9月11日 102(e)1996年9月11日PCT PCT 1995年3月7日PCT公布。 公开号WO95 / 24437 日期1995年9月14日描述了具有防粘性的聚合物多价丙二酸衍生物。 化合物包含与式(I)的基团连接的聚氨基酸。 在式(I)中,R 1和R 2一起形成含有至少一个选自R4,R5和R6的取代基的六元碳环或杂环。 R3是H,(CH2)mX或CH2O(CH2)mX1。 聚氨基酸和式II基团通过R4,R5或R6连接,或任选地经由式[Q1-(CH2)p-Q2-] r的间隔基连接。 A和B分别是O,S,NH,HN-CO,OC-NH,O-CO,OC-O,NH-CO-O,-O-CO-NH,S-CO,SC-O, CS-S,S-CS-OS,NH-CS-S,S-CS-NH或CH 2。 Z是吡喃糖,呋喃糖,开链多元醇或Y-X6。 Y是-O-(CX2,X3)n, - (CX2,X3)n,-CH2-(CX2,X3)n或具有至少一个取代基R9的饱和或不饱和六元碳 - 或杂环基,或 链-O-(CX2,X3)n或 - (CX2,X3)n和碳环或杂环基团的组合,其中R4,R5和R6独立地为H,OH,-O-(CH2 )qX4,-CH2O(CH2)qX5或HNC(O)CH3,X,X1,X2和X3独立地为H,NH2,COOH,OH,CH2OH,CH2NH2,C1-C20-烷基或C6-C10 芳基,X 4和X 5独立地是-NH-或-O-,X 6是OH或-C(R 3)(COOH)2。 m,n和q独立地可以是1-20。 在接头中,Q1是CH2或-CO-,Q2是-NH-或-CO-NH-,p是1-6,r是0或1.制备化合物的方法及其用作药物或诊断 代理商也被披露。

    Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity prepared therefrom
    8.
    发明授权
    Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity prepared therefrom 失效
    作为选择素拮抗剂的甘油模拟物和由其制备的具有抗炎活性的药物

    公开(公告)号:US06197752B1

    公开(公告)日:2001-03-06

    申请号:US08708475

    申请日:1996-09-05

    IPC分类号: A61K3170

    CPC分类号: C07D309/10 C07D307/20

    摘要: The invention relates to novel mimetics of the tetrasaccharides sialyl- Lewis-X (SLeX) and sialyl- Lewis-A (SLeA) having an improved action as inhibitors of cell adhesion, specifically a compound of the formula I in which R1 is —H, —CH3 or —CH2OH, R2 is —H or —OH, R3, R4 and R5 independently of one another are —H, C1-C4-alkyl or —OH, R6, R7, R8, R9 and R10 independently of one another are —H or C1-C4-alkyl D is —O—C(O)—, —C(O)—or —NR6—C(O)—, E is —CR7R8—, —NR7—, or a nitrogen heterocycle of the formula n is 1 or 2, m is 0 or 1, p is an integer from 0 to 10, q is 1 or 2 and X1 and X2 independently of one another are —H, —COOR9, —NR9R10, —OH, —OSO3H, —CH2COOR9 or —CH2OSO3H or together are ═O, to a process for preparing these compounds and to their use as pharmacological active compounds and diagnostic agents.

    摘要翻译: 本发明涉及具有作为细胞粘附抑制剂的改善作用的四糖唾液酸基-LX-X(SLeX)和唾液酸 - 路易斯-A(SLeA)的新型模拟物,特别是式Iin化合物,其中R 1为-H,-CH 3 或-CH 2 OH,R 2是-H或-OH,R 3,R 4和R 5彼此独立地是-H,C 1 -C 4 - 烷基或-OH,R 6,R 7,R 8,R 9和R 10彼此独立地是-H 或C 1 -C 4 - 烷基D为-OC(O) - , - C(O) - 或-NR 6 -C(O) - ,E为-CR 7 R 8 - , - NR 7 - 或式 2,m为0或1,p为0至10的整数,q为1或2,X 1和X 2彼此独立地为-H,-COOR 9,-NR 9 R 10,-OH,-OSO 3 H,-CH 2 COOR 9或-CH 2 OSO 3 H 或一起是= O,涉及制备这些化合物的方法及其作为药理活性化合物和诊断剂的用途。

    PROCESS FOR THE PRODUCTION OF BENZOFURANS
    9.
    发明申请
    PROCESS FOR THE PRODUCTION OF BENZOFURANS 有权
    生产苯甲醚的方法

    公开(公告)号:US20120065411A1

    公开(公告)日:2012-03-15

    申请号:US13321754

    申请日:2010-05-26

    CPC分类号: C07D307/80 C07C205/45

    摘要: A process for the production of 2-alkyl-3-aroyl-5-nitrobenzofurans by acylation of 2-(2-hydroxy-5-nitrophenyl)-1-aryl-ethanones and subsequent treatment of the esters with combinations of bases and proton acids or Lewis acids. This process can be used for the production of Dronedarone. Furthermore, novel intermediates for the manufacture of Dronedarone are provided.

    摘要翻译: 通过2-(2-羟基-5-硝基苯基)-1-芳基乙酰胺的酰化生产2-烷基-3-芳酰基-5-硝基苯并呋喃的方法,随后用碱和质子酸的组合处理酯 或路易斯酸。 该方法可用于生产决奈达隆。 此外,还提供了制备决奈达隆的新型中间体。